![Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study](https://cancerjournal.net/articles/2015/11/3/images/JCanResTher_2015_11_3_612_146056_t1.jpg)
Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study
![Table 2 from Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant Table 2 from Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant](https://d3i71xaburhd42.cloudfront.net/8502ba8141604eccd971b70828b6f88c895aa607/3-Table2-1.png)
Table 2 from Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant
![Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study](https://cancerjournal.net/articles/2015/11/3/images/JCanResTher_2015_11_3_612_146056_t5.jpg)
Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study
![Study on the role of primary systemic chemotherapy with anthracycline combination schedule in locally advanced breast cancer: long term follow up data - | Semantic Scholar Study on the role of primary systemic chemotherapy with anthracycline combination schedule in locally advanced breast cancer: long term follow up data - | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7d78229b477d28b17932f5e52ec97dc56a21d886/4-Table3-1.png)
Study on the role of primary systemic chemotherapy with anthracycline combination schedule in locally advanced breast cancer: long term follow up data - | Semantic Scholar
![Assessment of CBC Changes in Breast Cancer Patients Following Treatment with 5-Flourouracil, Adriamycin and Cyclophosphamide (FAC-Protocol) and Adriamycin and Cyclophosphamide (AC-Protocol) | Semantic Scholar Assessment of CBC Changes in Breast Cancer Patients Following Treatment with 5-Flourouracil, Adriamycin and Cyclophosphamide (FAC-Protocol) and Adriamycin and Cyclophosphamide (AC-Protocol) | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b048123e137a8bfd58af86342418693099311a16/4-Table1-1.png)
Assessment of CBC Changes in Breast Cancer Patients Following Treatment with 5-Flourouracil, Adriamycin and Cyclophosphamide (FAC-Protocol) and Adriamycin and Cyclophosphamide (AC-Protocol) | Semantic Scholar
![Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419635611-gr1.jpg)
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable
![Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. - Abstract - Europe PMC Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. - Abstract - Europe PMC](https://europepmc.org/articles/PMC359433/bin/29FFB1.jpg)
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. - Abstract - Europe PMC
Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents | PLOS ONE
![PDF] Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. | Semantic Scholar PDF] Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d570364e9d16703e6207f32528f8003b40217248/5-Table2-1.png)
PDF] Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. | Semantic Scholar
![Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/d6941f11-43c3-42dd-bd20-2da1b704c0b6/gr1_lrg.jpg)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial - The Lancet
![Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study](https://cancerjournal.net/articles/2015/11/3/images/JCanResTher_2015_11_3_612_146056_t4.jpg)